Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Erik H. F. Wong"'
Publikováno v:
Psychopharmacology
Background There is urgent need for new medications for psychiatric disorders. Mental illness is expected to become the leading cause of disability worldwide by 2030. Yet, the last two decades have seen the pharmaceutical industry withdraw from psych
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::067e4d97dc40a80e1282e44e6f6c1863
http://europepmc.org/articles/PMC7945970
http://europepmc.org/articles/PMC7945970
Publikováno v:
Psychopharmacology (Berl)
There is urgent need for new medications for psychiatric disorders. Mental illness is expected to become the leading cause of disability worldwide by 2030. Yet, the last two decades have seen the pharmaceutical industry withdraw from psychiatric drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80b86f51f473fb6eff15d3e9ef963af8
https://europepmc.org/articles/PMC8329796/
https://europepmc.org/articles/PMC8329796/
Autor:
James W. Murrough, Jessica J. Walsh, Angel Hawkins, Ming-Hu Han, Allyson K. Friedman, Erik H. F. Wong, Barbara Juarez, Stacy M. Ku, Hongxing Zhang, Dipesh Chaudhury, Maria Ribadeneira, David M. Dietz, Rachael L. Neve, Rhodora Cristina Calizo, Song Zhang
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-7 (2016)
Nature
Nature Communications
Nature
Nature Communications
Less than half of patients suffering from major depressive disorder, a leading cause of disability worldwide, achieve remission with current antidepressants, making it imperative to develop more effective treatment. A new therapeutic direction is eme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92eedc658811461d3d6f890c76949b61
https://doaj.org/article/27a25b5d540741f383c902474985df50
https://doaj.org/article/27a25b5d540741f383c902474985df50
Autor:
Edilio Borroni, Christer Halldin, Mohammed Shahid, Jussi Lehto, Mika Scheinin, Lars Farde, Sarah Grimwood, Sjoerd J. Finnema, Jukka Sallinen, Benny Bang-Andersen, Erik H. F. Wong
Publikováno v:
Psychopharmacology
Rationale This review attempts to summarize the current status in relation to the use of positron emission tomography (PET) imaging in the assessment of synaptic concentrations of endogenous mediators in the living brain. Objectives Although PET radi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dc3fde5c1449471a65c1fd5bc89bee8
https://doi.org/10.1007/s00213-015-3938-6
https://doi.org/10.1007/s00213-015-3938-6
Autor:
Denis J. David, Eduardo David Leonardo, Erik H. F. Wong, Alain M. Gardier, Amanda J. Williams, Reto Gadient, René Hen, Benjamin Adam Samuels, Jin Zhou
Publikováno v:
Neuropharmacology. 61:408-413
Depression is a polygenic and highly complex psychiatric disorder that is currently a major burden on society. Depression is highly heterogeneous in presentation and frequently exhibits high co-morbidity with other psychiatric and somatic deficits. C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::647abbb366f8074cc02f0e442570f5ed
https://doi.org/10.1016/j.neuropharm.2011.02.017
https://doi.org/10.1016/j.neuropharm.2011.02.017
Publikováno v:
The International Journal of Neuropsychopharmacology. 13:1269-1284
Innovation is essential for the identification of novel pharmacological therapies to meet the treatment needs of patients with psychiatric disorders. However, over the last 20 yr, in spite of major investments targets falling outside the classical am
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe416cb071741d254590168dd378f079
https://doi.org/10.1017/s1461145710000866
https://doi.org/10.1017/s1461145710000866
Publikováno v:
Journal of Psychopharmacology. 23:65-73
Asenapine is a novel psychopharmacologic agent under development for the treatment of schizophrenia and bipolar disorder. We determined and compared the human receptor binding affinities and functional characteristics of asenapine and several antipsy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d5403077dc8321d6bb1825079cb54b4
https://doi.org/10.1177/0269881107082944
https://doi.org/10.1177/0269881107082944
Publikováno v:
Psychopharmacology. 198:103-111
The novel psychopharmacologic agent, asenapine, has high affinity for a range of receptors including the dopaminergic receptors.We examined the long-term effects of multiple doses of asenapine on dopamine receptor subtypes: D(1)-like (D(1) and D(5)),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d460182ae3377a4faa67b6d8ebae3531
https://doi.org/10.1007/s00213-008-1098-7
https://doi.org/10.1007/s00213-008-1098-7
Autor:
Daniel P. Walker, Barbara A. Olson, Fusen Han, E. Jon Jacobsen, Raymond S. Hurst, Shaojuan Jia, Lester A. Dolak, Brandon J. Margolis, Nicole R. Higdon, Tatiana N. Vetman, David W. Piotrowski, Brian A. Staton, Matthew R. Hester, Luz A. Cortes-Burgos, Erik H. F. Wong, Theron M. Wall, Steven Charles Reitz, Vincent E. Groppi, Bruce N. Rogers, Kai S. Li, Brad A. Acker, Bruce A. Thornburgh, Paula M. Tinholt, Jason K. Myers, Mihály Hajós, Thomas J. Raub, Mark L. Wolfe, Karen M. Yates, William E. Hoffmann, Laura Fitzgerald, Donn G. Wishka, Eric P. Seest, Rodney R. Walters
Publikováno v:
Bioorganic & Medicinal Chemistry. 14:8219-8248
A novel set of azabicyclic aryl amides have been identified as potent and selective agonists of the alpha7 nAChR. A two-pronged approach was taken to improve the potential hERG liability of previously disclosed alpha7 nAChR agonist, PNU-282,987, whil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::058d11e4149544128cfd448da56d7569
https://doi.org/10.1016/j.bmc.2006.09.019
https://doi.org/10.1016/j.bmc.2006.09.019
Autor:
Arneric Sp, Karen K. Cook, Thomas J. Raub, Bruce N. Rogers, Mark L. Wolfe, Eric Jon Jacobsen, Vincent E. Groppi, Carey G, Brian A. Staton, Daniel P. Walker, Raymond S. Hurst, Luz A. Cortes-Burgos, Rodney R. Walters, Donn G. Wishka, Theron M. Wall, Jia S, Hanchar Aj, Karen M. Yates, Steven B. Sands, Bruce A. Thornburgh, Gold Lh, Soglia, Jason K. Myers, Franklin S, Steven Charles Reitz, Sabrina X. Zhao, Amit S. Kalgutkar, Nicole R. Higdon, Olson Kl, Erik H. F. Wong, Mihály Hajós, William E. Hoffmann
Publikováno v:
Journal of Medicinal Chemistry. 49:4425-4436
N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide (14, PHA-543,613), a novel agonist of the alpha7 neuronal nicotinic acetylcholine receptor (alpha7 nAChR), has been identified as a potential treatment of cognitive deficits in sch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09fbbbb19eb89de61edd6e606a68da00
https://doi.org/10.1021/jm0602413
https://doi.org/10.1021/jm0602413